What are the most important unanswered research questions in trial retention? A James Lind Alliance Priority Setting Partnership: the PRioRiTy II (Prioritising Retention in Randomised Trials) studyDan Brunsdon, Katie Gillies, Linda Biesty et al.|Trials|2019Cited by 116
Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trialMiriam Santer, Alison Layton, Jacqui Nuttall et al.|BMJ|2023Cited by 60
Topical preparations for the treatment of mild‐to‐moderate acne vulgaris: systematic review and network meta‐analysis*Beth Stuart, Miriam Santer, Emma Maund et al.|British Journal of Dermatology|2021Cited by 47
Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult womenSusanne Renz, Miriam Santer, Fay Chinnery et al.|BMJ Open|2021Cited by 17
Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCTMiriam Santer, Alison Layton, Megan Lawrence et al.|Health Technology Assessment|2024Cited by 7